drugset / Trial / NCT03261635
Ranibizumab Plus Indomethacin
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macular degeneration.
Timeline
- Start
- 2016-01-07
- Primary completion
- 2016-12-07
- Completion
- 2017-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indomethacin | Small molecule | 0.5 % | Topical |
| Background | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |